Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the US, affecting approximately a third of the US adult population. Obesity is the most common risk factor for NAFLD. NAFLD encompasses a spectrum from simple fatty liver to non-alcoholic steatohepatitis (NASH). Advanced NASH includes fibrosis and can progress to cirrhosis and hepatocellular carcinoma. The factors that promote the progression to NASH and fibrosis are not well known. It is widely accepted that this is caused by a """"""""second hit"""""""", but the nature of this """"""""second hit"""""""" remains elusive. It is well established that obesity causes an increase in the systemic levels of lipopolysaccharide (LPS). Additionally, we demonstrated that obesity increases levels of the damage- associated molecular pattern high mobility group box 1 (HMGB1) in mice and patients. Both LPS and HMGB1 trigger activation of Toll-like receptor 4 (TLR4) signaling, a pathway with major contributions to hepatic inflammation and fibrosis. Based on these data, we hypothesize that the progression of simple hepatic steatosis to NASH and fibrosis is triggered by activation of the TLR4 pathway by LPS and/or HMGB1. We seek to test this hypothesis by (1) examining whether TLR4 contributes to obesity-induced liver fibrosis, and (2) by determining the TLR4 ligands that drive progression in obesity-induced liver disease. To achieve these aims, we will use a model of diet-induced obesity that includes a high-fat, high-saturated fat diet and administration of fructose in the drinking water, mimicking a """"""""fast food"""""""" western-style diet (FFD diet). The FFD model has major advantages over the widely used methionine-choline-deficient model which typically leads to severe weight loss, and thus does not model human obesity and NAFLD. In contrast, FFD diet causes obesity, liver steatosis, NASH, and fibrosis and therefore is a physiological representation of human NAFLD. To study the role of TLR4, we will use mice with global and tissue-specific deletions of TLR4, including a novel and highly efficient method to selectively delete TLR4 in hepatic stellate cells. We will evaluate whether the deletion of TLR4 prevents hepatic inflammation and fibrosis. To study the role of LPS and HMGB1, we will evaluate whether pharmacological and genetic strategies that suppress LPS or HMGB1-mediated activation of TLR4 prevent obesity-driven hepatic inflammation and fibrosis. Results from these studies will improve our understanding of the mechanism that trigger disease progression in NAFLD and may point to new and clinically feasible therapeutic strategies.

Public Health Relevance

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in the US. It can be limited to simple fatty liver, or progress to non-alcoholic steatohepatitis (NASH) and cirrhosis, leading to severe and sometimes life-threatening complications. This project will investigate factors that promote progression of NAFLD to NASH and cirrhosis.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Small Research Grants (R03)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Mcbryde, Kevin D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Caviglia, Jorge Matias; Yan, Jun; Jang, Myoung-Kuk et al. (2018) MicroRNA-21 and Dicer are dispensable for hepatic stellate cell activation and the development of liver fibrosis. Hepatology 67:2414-2429
Yan, Jun; Caviglia, Jorge Matias; Schwabe, Robert F (2017) Animal models of HCC - When injury meets mutation. J Hepatol :
Wang, Xiaobo; Zheng, Ze; Caviglia, Jorge Matias et al. (2016) Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. Cell Metab 24:848-862
Huebener, Peter; Pradere, Jean-Philippe; Hernandez, Celine et al. (2015) The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest 125:539-50